Abstract

Marysabel Pinto Telis Silveira, Cezar Arthur Tavares Pinheiro, Marília Cruz Guttier, Tatiana Vanessa Silveira Pereira and Leila Beltrami Moreira

In the framework of pharmaceutical care, pharmacotherapy follow -up requires developing, implementing and monitoring an individual care plan to solve drug-related problems (DRP). HIV/AIDS patients use complex regimens, factor that could lessen adherence, which in turn, is associated with increased viral replication and the development of drug-resistance. Studies have shown that perception of side-effects also lessens adherence, reinforcing the need to prevent, identify and solve problems during antiretroviral treatment and to avoid DRP through pharmaceutical care. We describe a program of pharmaceutical care for HIV/AIDS patients and our planned randomized controlled trial. To evaluate pharmaceutical care program for HIV-infected patients using antiretroviral treatment, through the Dáder method. Randomized clinical trial method was used for this study. Patients will be interviewed when they collected drugs or have their medical visit. Data will be collected through questionnaires demographic and selfreported adherence to the antiretrovirals and self-efficacy, for 12 months. Viral load and CD4 will be measured. The pharmaceutical care program will consist of color labeling the antiretrovirals and giving patients a card with prescription information. This study will provide information about HIV-infected patients’ pharmaceutical care and will hopefully provide a validated model of pharmaceutical care for specialized health centers that will supplement their care.